Flow Pharma, Inc. – A California Biopharma Corporation
World Experts in Immunotherapy
Engineering and Manufacturing Medicines that Treat and Prevent Disease via Selective T-Cell Stimulation
Ebola Vaccine Creator
United States Department of Defense Vaccine Contractor
Flow Pharma, Inc. is a San Francisco Bay Area based, biopharmaceutical company. We program artificial intelligence to detect peptide targets on cancer cells and virus-infected cells. We then design, synthesize, and deliver identical peptides to stimulate therapeutic attack by the patient’s native immune system. These revolutionary T-cell stimulating targeted therapeutic peptides can be administered by injection or inhalation to selectively stimulate precision-enhanced immune competence.
We recently completed pre-clinical testing of FLOVID-20, a COVID-19 immunotherapy, at the United States National Laboratory at the University of Texas in Galveston. The test results demonstrate that FLOVID-20 immunized macaque monkeys, protecting them from COVID-19.
Flow Pharma has created FlowVax Survivin, a cancer immuno-therapeutic, targeting a neoantigen found in breast cancer. Our initial animal tests demonstrate a favorable response in triple negative breast cancer. Our additional cancer therapeutic development targets include HPV-related cancers of the cervix and head & neck.